Digestive Diseases and Sciences

, Volume 52, Issue 11, pp 2920–2925 | Cite as

A Meta-Analysis of Antibiotic Therapy for Active Ulcerative Colitis

  • Roja Rahimi
  • Shekoufeh Nikfar
  • Ali Rezaie
  • Mohammad Abdollahi
Original paper

Abstract

To systematically evaluate the efficacy of antibacterial therapy in ulcerative colitis, we carried out a meta-analysis of controlled clinical trials. Within the time period 1966 through September 2006, PUBMED, EMBASE, and SCOPUS were searched for clinical trial studies that investigated the efficacy of antibiotics in ulcerative colitis. We considered clinical remission as our key outcome of interest. Of 122 studies, 10 randomized placebo-controlled clinical trials matched our criteria and were included in the analysis (530 patients). All the studies used antibiotics as an adjunct therapy to conventional treatment of ulcerative colitis (i.e., corticosteroids and 5-aminosalycilic acid). Pooling of these trials yielded odds ratio (OR) of 2.14 (95% confidence interval [CI], 1.48–3.09; P<0.0001) in favor of antimicrobial therapy. Meta-analysis of short-term trials (5–14 days) showed a higher rate of clinical remission in patients treated with antibiotics (OR, 2.02; 95% CI, 1.36–3). These results suggest that adjunctive antibacterial therapy is effective for induction of clinical remission in ulcerative colitis.

Keywords

Ulcerative colitis Antibiotics Clinical remission Meta-analysis 

REFERENCES

  1. 1.
    Shen EH, Das KM (2004) Current therapeutic recommendations: infliximab for ulcerative colitis. J Clin Gastroenterol 38:741–745PubMedCrossRefGoogle Scholar
  2. 2.
    Lichtenstein GR (2001) Is infliximab effective for induction of remission in patients with ulcerative colitis? Inflamm Bowel Dis 7:89–93PubMedCrossRefGoogle Scholar
  3. 3.
    Hanauer SB, Sparrow M (2004) Therapy of ulcerative colitis. Curr Opin Gastroenterol 20:345–350PubMedCrossRefGoogle Scholar
  4. 4.
    Hanauer SB (2006) Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 12:S3–S9PubMedCrossRefGoogle Scholar
  5. 5.
    Andus T, Gross V (2000) Etiology and pathophysiology of inflammatory bowel disease – environmental factors. Hepatogastroenterology 47:29–43PubMedGoogle Scholar
  6. 6.
    Koutroubakis I, Manousos ON, Meuwissen SG, Pena AS (1996) Environmental risk factors in inflammatory bowel disease. Hepatogastroenterology 43:381–393PubMedGoogle Scholar
  7. 7.
    Sartor RB (1997) Review article: role of the enteric microflora in the pathogenesis of intestinal inflammation and arthritis. Aliment Pharmacol Ther 11 (Suppl 3):17–22, discussion 22–23PubMedGoogle Scholar
  8. 8.
    Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M, Lochs H (2002) Mucosal flora in inflammatory bowel disease. Gastroenterology 122:44–54PubMedCrossRefGoogle Scholar
  9. 9.
    Gionchetti P, Rizzello F, Lammers KM, Morselli C, Sollazzi L, Davies S, Tambasco R, Calabrese C, Campieri M (2006) Antibiotics and probiotics in treatment of inflammatory bowel disease. World J Gastroenterol 12:3306–3313PubMedGoogle Scholar
  10. 10.
    Nomura T, Ohkusa T, Okayasu I, Yoshida T, Sakamoto M, Hayashi H, Benno Y, Hirai S, Hojo M, Kobayashi O, Terai T, Miwa H, Takei Y, Ogihara T, Sato N (2005) Mucosa-associated bacteria in ulcerative colitis before and after antibiotic combination therapy. Aliment Pharmacol Ther 21:1017–1027PubMedCrossRefGoogle Scholar
  11. 11.
    Rizzello F, Gionchetti P, Venturi A, Ferretti M, Peruzzo S, Raspanti X, Picard M, Canova N, Palazzini E, Campieri M (1998) Rifaximin systemic absorption in patients with ulcerative colitis. Eur J Clin Pharmacol 54:91–93PubMedCrossRefGoogle Scholar
  12. 12.
    Casellas F, Borruel N, Papo M, Guarner F, Antolin M, Videla S, Malagelada JR (1998) Antiinflammatory effects of enterically coated amoxicillin-clavulanic acid in active ulcerative colitis. Inflamm Bowel Dis 4:1–5PubMedCrossRefGoogle Scholar
  13. 13.
    Parlak E, Dagli U, Ulker A, Alkim C, Sahin B (2001) Comparison of 5-amino salicylic acid plus glucocorticosteroid with metronidazole and ciprofloxacin in patients with active ulcerative colitis. J Clin Gastroenterol 33:85–86PubMedCrossRefGoogle Scholar
  14. 14.
    Gilat T, Leichtman G, Delpre G, Eshchar J, Bar Meir S, Fireman Z (1989) A comparison of metronidazole and sulfasalazine in the maintenance of remission in patients with ulcerative colitis. J Clin Gastroenterol 11:392–395PubMedCrossRefGoogle Scholar
  15. 15.
    Gilat T, Suissa A, Leichtman G, Delpre G, Pavlotzky M, Grossman A, Fireman Z (1987) A comparative study of metronidazole and sulfasalazine in active, not severe, ulcerative colitis. An Israeli multicenter trial. J Clin Gastroenterol 9:415–417PubMedCrossRefGoogle Scholar
  16. 16.
    Ohkusa T, Nomura T, Terai T, Miwa H, Kobayashi O, Hojo M, Takei Y, Ogihara T, Hirai S, Okayasu I, Sato N (2005) Effectiveness of antibiotic ombination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up. Scand J Gastroenterol 40:1334–1342PubMedCrossRefGoogle Scholar
  17. 17.
    Mantzaris GJ, Archavlis E, Christoforidis P, Kourtessas D, Amberiadis P, Florakis N, Petraki K, Spiliadi C, Triantafyllou G (1997) A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am J Gastroenterol 92:454–456PubMedGoogle Scholar
  18. 18.
    Burke DA, Axon AT, Clayden SA, Dixon MF, Johnston D, Lacey RW (1990) The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther 4:123–129PubMedCrossRefGoogle Scholar
  19. 19.
    Gionchetti P, Rizzello F, Ferrieri A, Venturi A, Brignola C, Ferretti M, Peruzzo S, Miglioli M, Campieri M (1999) Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid treatment: a double-blind, placebo-controlled trial. Dig Dis Sci 44:1220–1221PubMedCrossRefGoogle Scholar
  20. 20.
    Turunen U, Farkkila, Valtonen V (1998) Long-term treatment of ulcerative colitis with ciprofloxacin. Gastroenterology 117:282–283Google Scholar
  21. 21.
    Lobo AJ, Burke DA, Sobala GM, Axon AT (1993) Oral tobramycin in ulcerative colitis:effect on maintenance of remission. Aliment Pharmacol Ther 7:155–158PubMedCrossRefGoogle Scholar
  22. 22.
    Chapman RW, Selby WS, Jewell DP (1986) Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 27:1210–1212PubMedCrossRefGoogle Scholar
  23. 23.
    Mantzaris GJ, Hatzis A, Kontogiannis P, Triadaphyllou G (1994) Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 89:43–46PubMedGoogle Scholar
  24. 24.
    Mantzaris GJ, Petraki K, Archavlis E, Amberiadis P, Kourtessas D, Christidou A, Triantafyllou G (2001) A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol 36:971–974PubMedCrossRefGoogle Scholar
  25. 25.
    Dickinson RJ, O’Connor HJ, Pinder I, Hamilton I, Johnston D, Axon AT (1985) Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 26:1380–1384PubMedCrossRefGoogle Scholar
  26. 26.
    Jahanshahi G, Motavasel V, Rezaie A, Hashtroudi AA, Daryani NE, Abdollahi M (2004) Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases. Dig Dis Sci 49(11–12):1752–1757PubMedCrossRefGoogle Scholar
  27. 27.
    Rezaie A, Parker R, Abdollahi M (2006) Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci (in press)Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Roja Rahimi
    • 1
  • Shekoufeh Nikfar
    • 2
  • Ali Rezaie
    • 3
  • Mohammad Abdollahi
    • 1
    • 4
  1. 1.Faculty of Pharmacy and Pharmaceutical Sciences Research CenterTehran University of Medical SciencesTehranIran
  2. 2.Drug Selecting CommitteeFood and Drug OrganizationTehranIran
  3. 3.Department of Community Health Sciences, Faculty of MedicineUniversity of CalgaryCalgaryCanada
  4. 4.Department of Toxicology & Pharmacology, Faculty of Pharmacy, and Pharmaceutical Sciences Research CenterTehran University of Medical SciencesTehranIran

Personalised recommendations